scholarly journals A Rare Case of Metastatic Malignant Melanoma to the Colon from an Unknown Primary

2014 ◽  
Vol 2014 ◽  
pp. 1-4
Author(s):  
Preethi Reddy ◽  
Courtney Walker ◽  
Bianca Afonso
Keyword(s):  
Overall Survival ◽  
Gastrointestinal Tract ◽  
Malignant Melanoma ◽  
Metastatic Melanoma ◽  
Rare Case ◽  
Metastatic Malignant Melanoma ◽  
Unknown Primary ◽  
Gastrointestinal Metastasis ◽  
Low Prevalence

Metastatic melanoma from an unknown primary (MUP) is rare; its occurrence in the gastrointestinal tract is of exceedingly low prevalence. We report a case of a 73-year-old man with metastatic malignant melanoma to the colon from an unknown primary. The rarity of MUP and importance of screening for gastrointestinal metastasis in patients with malignant melanoma are discussed along with the role of surgical resection in improving prognosis and overall survival.

scholarly journals Malignant melanoma without primary, presenting as solitary pulmonary nodule: a case report

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
George Tsaknis ◽  
Muhammad Naeem ◽  
Advitya Singh ◽  
Siddharth Vijayakumar
Keyword(s):  
Lung Cancer ◽  
Malignant Melanoma ◽  
Pulmonary Nodule ◽  
Solitary Pulmonary Nodule ◽  
Past History ◽  
White Male ◽  
Pulmonary Nodules ◽  
Metastatic Malignant Melanoma ◽  
Unknown Primary ◽  
Solitary Pulmonary Nodules

Abstract Background Solitary pulmonary nodules are the most common incidental finding on chest imaging. Their management is very well defined by several guidelines, with risk calculators for lung cancer being the gold standard. Solitary intramuscular metastasis combined with a solitary pulmonary nodule from malignant melanoma without a primary site is rare. Case presentation A 57-year-old white male was referred to our lung cancer service with solitary pulmonary nodule. After positron-emission tomography, we performed an ultrasound-guided core needle biopsy of an intramuscular solitary lesion, not identified on computed tomography scan, and diagnosed metastatic malignant melanoma. The solitary pulmonary nodule was resected and also confirmed metastatic melanoma. There was no primary skin lesion. The patient received oral targeted therapy and is disease-free 5 years later. Conclusions Clinicians dealing with solitary pulmonary nodules must remain vigilant for other extrathoracic malignancies even in the absence of obvious past history. Lung metastasectomy may have a role in metastatic malignant melanoma with unknown primary.

scholarly journals Diffuse Melanosis and Ascites due to Metastatic Malignant Melanoma

2008 ◽  
Vol 8 ◽  
pp. 556-557 ◽  
Author(s):  
Elena Sendagorta ◽  
Angel Pizarro ◽  
Marta Feito ◽  
Matias Mayor ◽  
Paloma Ramírez ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Metastatic Melanoma ◽  
Female Patient ◽  
Metastatic Malignant Melanoma ◽  
Current Evidence ◽  
Rare Entity ◽  
Skin Hyperpigmentation

We present a female patient who developed mucosal and skin hyperpigmentation due to metastatic malignant melanoma. Diffuse cutaneus melanosis is a rare entity that complicates a small percentage of metastatic melanomas, confering a fatal prognosis. We discuss briefly the current evidence on pathogenesis of melanosis arising from metastatic melanoma.

Adrenalectomy for Metastatic Melanoma: Current Role in the Age of Nonsurgical Treatments

2015 ◽  
Vol 81 (10) ◽  
pp. 1005-1009 ◽  
Author(s):  
Devin C. Flaherty ◽  
Gary B. Deutsch ◽  
Daniel D. Kirchoff ◽  
Jihey Lee ◽  
Kelly T. Huynh ◽  
...  
Keyword(s):  
Overall Survival ◽  
Metastatic Melanoma ◽  
Surgical Resection ◽  
Stage Iv ◽  
Nonoperative Treatment ◽  
Unknown Primary ◽  
Adrenal Metastases ◽  
Term Survival ◽  
Relative Value ◽  
Resection Of Metastases

Surgical resection of metastases to the adrenal gland can improve overall survival of patients with stage IV melanoma, but its relative value with respect to current nonsurgical therapies is unknown. We hypothesized that surgery remains an optimal first-line treatment approach for resectable adrenal metastases. A search of our institution's prospectively collected melanoma database identified stage IV patients treated for adrenal metastases between January 1, 2000, and August 11, 2014. The 91 study patients had a mean age of 60.3 years at diagnosis of adrenal metastasis and 24 had undergone adrenalectomy. Improved survival was associated with an unknown primary lesion, surgical resection, and nonsurgical therapies. Median overall survival from diagnosis of adrenal metastases was 29.2 months with adrenalectomy versus 9.4 months with nonoperative treatment. Adrenalectomy, either as complete metastasectomy or targeted to lesions resistant to systemic therapy, is associated with improved long-term survival in metastatic melanoma.

Ganglioside analysis of metastatic malignant melanoma with unknown primary lesion

1990 ◽  
Vol 1 (2) ◽  
pp. 116
Author(s):  
Junji Nakano ◽  
Takashi Imamura ◽  
Sumiko Hamanaka ◽  
Takahisa Ota ◽  
Chidori Asagami
Keyword(s):  
Malignant Melanoma ◽  
Metastatic Malignant Melanoma ◽  
Primary Lesion ◽  
Unknown Primary

Prognostic relevance of pretreatment soluble vascular endothelial growth factors (A,C,D) and their receptors (R1, R2, and R3) in advanced melanoma patients

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 8540-8540 ◽  
Author(s):  
R. Mouawad ◽  
C. Soubrane ◽  
D. Khayat
Keyword(s):  
Overall Survival ◽  
Growth Factors ◽  
Malignant Melanoma ◽  
Univariate Analysis ◽  
Metastatic Malignant Melanoma ◽  
Vascular Endothelial Growth Factors ◽  
Vascular Endothelial ◽  
Melanoma Patients ◽  
Endothelial Growth Factors ◽  
Disease Free

8540 Background and aims: Circulating vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs) were described as prognostic factors in several cancers. The aim of this study is to evaluate the prognostic values of these parameters in metastatic malignant melanoma diseases. Methods and Patients: Using enzyme-linked immunosorbent assays, VEGFs (A, C, D) and their receptors (1, 2, and 3) were measured in sera of 75 patients with metastatic malignant melanoma in comparison to 30 healthy controls. Disease free survival (DFS) and overall survival (OS) were calculated from the beginning of the treatment until either the progression or the death and analyzed using the Kaplan-Meier method. Results: Pretreatment median sVEGF-A, sVEGF-C as well as VEGFR-3 levels were significantly higher in MMM patients as compared to healthy ones p=0.0017, p=0.005, p<0.00001 respectively). None of the studied markers correlated with gender, age or LDH levels. An inverse correlation between soluble VEGFR-2 and VEGF-D levels was observed (r=−0.33 p=0.040). High soluble VEGF-C and VEGFR-3 were correlated to high tumor burden (p=0.02, p=0.045). However, a relationship with lymph node metastasis was observed with sVEGF-A but not with sVEGFR-3. As shown by univariate analysis, only elevated levels of sVEGF-R1 concentration were found to exert a significantly unfavorable impact on both disease-free (χ2=6.64, p= 0.014) and overall survival (χ2=8.03, p= 0.0046). Conclusions: Our results suggest that, in metastatic malignant melanoma patients, soluble VEGF-A and VEGF-R3 pretreatment levels may prospectively identify high-risk patients with a worse prognosis; serum VEGFR-1 level may be a predictive factor of time to progression and overall survival. A multivariate analysis (Cox test) is ongoing in order to confirm if this parameter is an independent prognostic factor. No significant financial relationships to disclose.

Biventricular cavity obliteration by metastatic malignant melanoma: Role of magnetic resonance imaging in the diagnosis

1987 ◽  
Vol 114 (5) ◽  
pp. 1249-1253 ◽  
Author(s):  
Aaron J. Gindea ◽  
Pamela Steele ◽  
William M. Rumancik ◽  
Montserrat Culubret ◽  
Helen Feiner ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Malignant Melanoma ◽  
Metastatic Malignant Melanoma ◽  
Resonance Imaging ◽  
Cavity Obliteration
Sign in / Sign up

Export Citation Format

Share Document